Record overview
Status and phase
Status: COMPLETED
Phase: PHASE2, PHASE3
Sponsor: Merck Sharp & Dohme LLC
Condition: Non Small Cell Lung Cancer (NSCLC)
NCT01905657
Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | few_sites_large_trial_signal
Stopped reason
Context when available
No stop reason available in the current public record.